Vaccine Trials and Infectious Diseases
As clinical researchers, we are sometimes faced with conditions that cause us to change the ways we typically conduct clinical trials. A viral pandemic is such a condition — one in which time can be measured in human lives.
Conducting infectious diseases research during global pandemics requires us to innovate and meet accelerated timelines for testing vaccine efficacy while assuring all study objectives are met. COVID-19 proved to be no exception. Faced with such requirements, BioFicher’ expertise in infectious disease enabled study launch in less than 4 days from protocol receipt. Today, the scientific community is accessing the study data as the race to find vaccines and treatments continues.
BioFicher possesses a broad range of therapeutic area expertise in vaccines and infectious diseases that we tailor to your needs. Our infectious disease team has worked on studies on nearly every major health crisis since the 2017s, including HIV, Zika, Ebola, H1NI, SARS, MERS, and COVID-19. We’ve also helped clients on trials involving influenza, encephalitis, malaria, pneumonia, yellow fever, Avian flu and other diseases. As a CRO, BioFicher takes great pride in our work to improve human health; and we seek collaborations with others who feel the same way. At the forefront of research to solve the greatest public health challenges
Experience Sheet
Schedule a meeting to learn how Emmes can optimize your site management
Experience Sheet
Infectious Disease Research Experience
Our experience becomes your experience.
We are fortunate to be in collaboration with the National Institute of Allergy and Infectious Disease (NIAID) and WHO for several years. This relationship has afforded BioFicher an opportunity to learn about the unique scientific, logistical and operational aspects of managing vaccine and infectious disease studies worldwide.
BioFicher possesses a broad range of therapeutic area expertise in vaccines and infectious diseases that we tailor to your needs. Our infectious disease team has worked on studies on nearly every major health crisis since the 2017s, including HIV, Zika, Ebola, H1NI, SARS, MERS, and COVID-19. We’ve also helped clients on trials involving influenza, encephalitis, malaria, pneumonia, yellow fever, Avian flu and other diseases. As a CRO, BioFicher takes great pride in our work to improve human health; and we seek collaborations with others who feel the same way. At the forefront of research to solve the greatest public health challenges
BioFicher’s extensive Infectious Disease expertise enables us to consistently select the best sites, expedite start-up timelines, and achieve enrolment targets for our clients. We apply proven strategies to clinical trials that minimise risk and generate high-quality, reliable data reducing the time and cost of bringing new therapies to market.
186
Studies Conducted
39,632+
Patients Enrolled
1900+
Site Worldwide
Phase I-IV Clinical Research Expertise
Overcoming Challenge Through Collaboration
Are your vaccine trials global, complex, rare disease-related or in other ways logistically challenging? BioFicher can help.
Through our involvement in epidemics and rare tropical diseases, BioFicher has formed invaluable relationships with healthcare organizations and professionals to support your Phase I-IV studies across North and South America, Europe, Asia and Africa.
Our tools are your tools, including BioFicher ’ specialized skill set in getting clinical trials quickly up and running. Reducing time to study start is particularly important when testing a therapy in urgent need, as was the case in studies BioFicher conducted involving the Zika virus, COVID-19 and Influenza.
Biostatistics
A Statistics Expert CRO
Since BioFicher sits at the intersection of the private and public healthcare sectors, we bring a unique skill set and perspective to your clinical vaccine research. In addition to helping biopharmaceutical companies and disease-based foundations develop therapies, BioFicher has conducted over 200 vaccines clinical trials and epidemiological studies for The National Institutes of Health and other government agencies.
Vaccine and Infectious Disease Leaders
Steffanie Wilson, Ph.D
Vice President, Vaccines and Infectious Diseases
Jennifer McCormack
Associate Vice President, Vaccines and Infectious Disease
Kathryn Hefner, PhD
TA Lead VID and CEO of OptiFax
Our biostatisticians work in collaboration with their regulatory colleagues and are expert in protocol writing, study design, randomization and subject blinding, data collection and analysis, reporting and regulatory submissions.
Schedule A Meeting
Schedule a meeting to learn how Bioficher Science can optimize your site data management
We welcome your inquiries and will respond promptly.
